Alto Neuroscience
12 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| ALTO-100 in Bipolar Disorder With Depression (BD-D) (NCT06656416) | Alto Neuroscience | 2024-10-02 |
| Study of ALTO-101 in Patients With Schizophrenia (NCT06502964) | Alto Neuroscience | 2024-06-11 |
| PD, PK, and Safety of ALTO-203 in Patients With MDD (NCT06391593) | Alto Neuroscience | 2024-03-25 |
| Study of ALTO-300 in MDD (NCT05922878) | Alto Neuroscience | 2023-06-08 |
| Phase 2b Study of ALTO-100 in MDD (NCT05712187) | Alto Neuroscience | 2023-01-10 |
| Pilot Decentralized Trial (NCT05419869) | Alto Neuroscience | 2022-06-01 |
| ALTO-300 in Depression (ALTO-300-004) (NCT05157945) | Alto Neuroscience | 2022-02-03 |
| ALTO-100 in MDD and/or PTSD (NCT05117632) | Alto Neuroscience | 2021-12-20 |
| ALTO-300 in Depression (NCT05118750) | Alto Neuroscience | 2021-12-13 |
| Leveraging EEG for Antidepressant Prediction With Duloxetine and Bupropion (NCT04388189) | Alto Neuroscience | 2020-10-15 |
| Leveraging EEG for Antidepressant Prediction With Sertraline and Escitalopram (NCT04388202) | Alto Neuroscience | 2020-10-15 |
Track Alto Neuroscience automatically
Every clearance here is in the API, with alerts when new ones post.